Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIR | O00625 | 4/20 | 0.58 |
| ▸ | HSF1 | Q00613 | 7/20 | 0.55 |
| ▸ | BRAF | P15056 | 6/20 | 0.55 |
| ▸ | GSK3B | P49841 | 2/20 | 0.55 |
| ▸ | RAF1 | P04049 | 2/20 | 0.51 |
| ▸ | ARAF | P10398 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.49 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16620920 | 0.84 | HSF1 (0.62) | PIRHSF1BRAFGSK3BNPC1 | |
| SCHEMBL16621213 | 0.83 | HPGDS (0.52) | PIRHSF1BRAFGSK3BRAF1 | |
| SCHEMBL5897180 | 0.80 | MAPK14 (0.73) | BRAFRAF1MAPK14MAPK11 | |
| SCHEMBL16620957 | 0.78 | HSF1 (0.63) | PIRHSF1BRAFGSK3BNPC1 | |
| SCHEMBL5897069 | 0.77 | MAPK14 (0.60) | BRAFRAF1MAPK14 | |
| SCHEMBL18109908 | 0.77 | HSF1 (0.67) | PIRHSF1BRAFGSK3BNPC1 | |
| SCHEMBL16621177 | 0.77 | HSF1 (0.67) | PIRHSF1BRAFGSK3BNPC1 | |
| SCHEMBL16621279 | 0.76 | ADORA2A (0.74) | PIRHSF1BRAFGSK3BNPC1 | |
| SCHEMBL16620850 | 0.76 | HSF1 (0.60) | PIRHSF1BRAFGSK3BNPC1 | |
| SCHEMBL16621320 | 0.76 | HSF1 (0.50) | PIRHSF1BRAFGSK3BNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254110-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECH LTD (GB) | 2024-08-01 | — | — | US | claimed |
| EP-3521286-B1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECH LTD (GB) | 2021-09-29 | — | — | EP | claimed |
| EP-3521286-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | Cancer Research Technology Ltd. (GB) | 2019-08-07 | — | — | EP | claimed |
| US-20190106413-A1 | INHIBITOR COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-04-11 | — | — | US | claimed |
| EP-3052492-B1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECH LTD (GB) | 2019-03-27 | — | — | EP | claimed |
| US-20170037036-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR I | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-02-09 | — | — | US | claimed |
| US-20160289216-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-10-06 | — | — | US | claimed |
| EP-3052492-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | Cancer Research Technology Limited (GB) | 2016-08-10 | — | — | EP | claimed |
| WO-2015049535-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-04-09 | — | — | WO | claimed |
| US-20240254110-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECH LTD (GB) | 2024-08-01 | — | — | US | disclosed |
| US-11787786-B2 | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-10-17 | — | — | US | disclosed |
| US-20220220097-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-07-14 | — | — | US | disclosed |
| EP-3521286-B1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECH LTD (GB) | 2021-09-29 | — | — | EP | disclosed |
| US-11124501-B2 | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor I | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-09-21 | — | — | US | disclosed |
| US-10189821-B2 | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor I | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-01-29 | — | — | US | disclosed |
| US-9701664-B2 | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-07-11 | — | — | US | disclosed |
| US-20170037036-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR I | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-02-09 | — | — | US | disclosed |
| US-20160289216-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-10-06 | — | — | US | disclosed |
| EP-3052492-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | Cancer Research Technology Limited (GB) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015049535-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106413-A1 | INHIBITOR COMPOUNDS | HSF1, HSP90AB1, HSP90AA1 | PIR 3555/4885HSF1 1/4885BRAF 307/4885 |
| US-10189821-B2 | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor I | HSF1, HSP90AB1, HSPB1 | PIR 3676/4885HSF1 1/4885BRAF 1660/4885 |
| US-20240254110-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | HSF1, HSP90AB1, HSPB1 | PIR 3795/4885HSF1 1/4885BRAF 1518/4885 |
| US-20170037036-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR I | HSF1, HSP90AB1, HSPB1 | PIR 3676/4885HSF1 1/4885BRAF 1660/4885 |
| US-20160289216-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | HSF1, HSP90AB1, HSPB1 | PIR 3817/4885HSF1 1/4885BRAF 1509/4885 |
| US-11787786-B2 | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1 | HSF1, HSP90AB1, HSPB1 | PIR 3795/4885HSF1 1/4885BRAF 1518/4885 |
| US-20220220097-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | HSF1, HSP90AB1, HSPB1 | PIR 3795/4885HSF1 1/4885BRAF 1518/4885 |
| US-11124501-B2 | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor I | HSF1, HSP90AB1, HSPB1 | PIR 3676/4885HSF1 1/4885BRAF 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.